Transfemoral aortic valve implantation using a self-expanding transcatheter heart valve without pre-dilation


      • Implantation of the Acurate neo without predilatation is feasible in select patients.
      • Procedure and fluoroscopy time are thereby significantly shorter.
      • The rate of relevant aortic regurgitation or postdilatation is not negatively affected.
      • Hemodynamic stability is maintained throughout the entire procedure.
      • This concept is straightforward and currently represents the gentlest TAVI approach.



      The aim of the present study was to investigate whether transfemoral implantation of the Acurate neo transcatheter heart valve without pre-dilation is feasible.


      Between December 2014 and December 2016, 294 patients were treated with the Acurate neo prosthesis at our center. Of these, 72 cases were performed without pre-dilation. The decision to omit pre-dilation was at the discretion of the operator, preferably in the case of mild to moderate aortic valve calcification (AVC). Propensity matching (1:1) resulted in 48 cases in each group. Main outcomes of interest were device success according to VARC-2 criteria, residual aortic regurgitation (AR) ≥2°, and rate of post-dilation.


      Median [IQR] age in patients without pre-dilation was 82.7 years [78.6–85.6], STS score was 4.6% [3.4–6.1], and AVC-score was 1436 AU [1043–1682] with mild and moderate AVC in 63.9% and 36.1% of cases, respectively. Device success was achieved in 94.4% of cases, post-dilation was necessary in 26.4%, and one (1.4%) patient had moderate AR. In the matched population, there were no differences regarding device success, rate of AR ≥2°, need for post-dilation, and post-procedural mean gradient, but the group without pre-dilation had shorter procedure (34.0 min [27.0–38.8] vs. 43.0 min [34.3–52.0]; p < 0.001) and fluoroscopy times (7.4 min [5.7–9.0] vs. 9.9 min [7.9–13.5]; p < 0.001).


      In select patients with mild to moderate AVC, transfemoral implantation of the Acurate neo without pre-dilation is feasible and safe. This allows for a straightforward procedure that may be performed without rapid pacing in the majority of cases.


      AR (aortic regurgitation), AVCS (aortic valve calcium score), AVCdens (aortic valve calcium density), LVOT (left ventricular outflow tract), TAVI (transcatheter aortic valve implantation), MDCT (multidetector computed tomography)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Adams D.H.
        • Popma J.J.
        • Reardon M.J.
        • Yakubov S.J.
        • Coselli J.S.
        • Deeb G.M.
        • et al.
        Transcatheter aortic-valve replacement with a self-expanding prosthesis.
        N. Engl. J. Med. 2014; 370: 1790-1798
        • Hamm C.W.
        • Mollmann H.
        • Holzhey D.
        • Beckmann A.
        • Veit C.
        • Figulla H.R.
        • et al.
        The German aortic valve registry (GARY): in-hospital outcome.
        Eur. Heart J. 2014; 35: 1588-1598
        • Siontis G.C.
        • Praz F.
        • Pilgrim T.
        • Mavridis D.
        • Verma S.
        • Salanti G.
        • et al.
        Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials.
        Eur. Heart J. 2016;
        • Thourani V.H.
        • Kodali S.
        • Makkar R.R.
        • Herrmann H.C.
        • Williams M.
        • Babaliaros V.
        • et al.
        Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis.
        Lancet. 2016; 387: 2218-2225
        • Ben-Dor I.
        • Pichard A.D.
        • Satler L.F.
        • Goldstein S.A.
        • Syed A.I.
        • Gaglia Jr., M.A.
        • et al.
        Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients.
        JACC Cardiovasc. Interv. 2010; 3: 1150-1156
        • Buchanan G.L.
        • Chieffo A.
        • Montorfano M.
        • Colombo A.
        Left main thrombotic occlusion following balloon aortic valvuloplasty for severe aortic stenosis.
        Can. J. Cardiol. 2012; 28 (e13-5): 759
        • Selle A.
        • Figulla H.R.
        • Ferrari M.
        • Rademacher W.
        • Goebel B.
        • Hamadanchi A.
        • et al.
        Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion.
        Clin. Res. Cardiol. 2014; 103: 902-911
        • Haberthur D.
        • Lutter G.
        • Appel M.
        • Attmann T.
        • Schramm R.
        • Schmitz C.
        • et al.
        Percutaneous aortic valve replacement: valvuloplasty studies in vitro.
        Eur. J. Cardiothorac. Surg. 2011; 39: 631-634
        • Grube E.
        • Naber C.
        • Abizaid A.
        • Sousa E.
        • Mendiz O.
        • Lemos P.
        • et al.
        Feasibility of transcatheter aortic valve implantation without balloon pre-dilation: a pilot study.
        JACC Cardiovasc. Interv. 2011; 4: 751-757
        • Mollmann H.
        • Kim W.K.
        • Kempfert J.
        • Blumenstein J.
        • Liebetrau C.
        • Nef H.
        • et al.
        Transfemoral aortic valve implantation of Edwards SAPIEN XT without predilatation is feasible.
        Clin. Cardiol. 2014; 37: 667-671
        • Kim W.K.
        • Praz F.
        • Blumenstein J.
        • Liebetrau C.
        • Gaede L.
        • Van Linden A.
        • et al.
        Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation.
        Catheter. Cardiovasc. Interv. 2016;
        • Kempfert J.
        • Meyer A.
        • Kim W.K.
        • van Linden A.
        • Arsalan M.
        • Blumenstein J.
        • et al.
        First experience without pre-ballooning in transapical aortic valve implantation: a propensity score-matched analysis.
        Eur. J. Cardiothorac. Surg. 2015; 47 (discussion 8): 31-38
        • Mollmann H.
        • Diemert P.
        • Grube E.
        • Baldus S.
        • Kempfert J.
        • Abizaid A.
        Symetis ACURATE TF aortic bioprosthesis.
        EuroIntervention. 2013; 9: S107-S110
        • Joint Task Force on the Management of Valvular Heart Disease of the European Society of C
        • European Association for Cardio-Thoracic S
        • Vahanian A.
        • Alfieri O.
        • Andreotti F.
        • Antunes M.J.
        • et al.
        Guidelines on the management of valvular heart disease (version 2012).
        Eur. Heart J. 2012; 33: 2451-2496
        • Opolski M.P.
        • Kim W.K.
        • Liebetrau C.
        • Walther C.
        • Blumenstein J.
        • Gaede L.
        • et al.
        Diagnostic accuracy of computed tomography angiography for the detection of coronary artery disease in patients referred for transcatheter aortic valve implantation.
        Clin. Res. Cardiol. 2015; 104: 471-480
        • Pibarot P.
        • Dumesnil J.G.
        Low-flow, low-gradient aortic stenosis with normal and depressed left ventricular ejection fraction.
        J. Am. Coll. Cardiol. 2012; 60: 1845-1853
        • Agatston A.S.
        • Janowitz W.R.
        • Hildner F.J.
        • Zusmer N.R.
        • Viamonte Jr., M.
        • Detrano R.
        Quantification of coronary artery calcium using ultrafast computed tomography.
        J. Am. Coll. Cardiol. 1990; 15: 827-832
        • Greason K.L.
        • Williamson E.E.
        • Suri R.M.
        • Mathew V.
        High Agatston aortic valve calcium score predicts transcatheter paravalvular aortic regurgitation.
        J. Thorac. Cardiovasc. Surg. 2014; 147: 1991
        • Kappetein A.P.
        • Head S.J.
        • Genereux P.
        • Piazza N.
        • van Mieghem N.M.
        • Blackstone E.H.
        • et al.
        Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document.
        J. Am. Coll. Cardiol. 2012; 60: 1438-1454
        • Zamorano J.L.
        • Badano L.P.
        • Bruce C.
        • Chan K.L.
        • Goncalves A.
        • Hahn R.T.
        • et al.
        EAE/ASE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease.
        J. Am. Soc. Echocardiogr. 2011; 24: 937-965
        • Siontis G.C.
        • Juni P.
        • Pilgrim T.
        • Stortecky S.
        • Bullesfeld L.
        • Meier B.
        • et al.
        Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis.
        J. Am. Coll. Cardiol. 2014; 64: 129-140
        • Möllmann H.
        30-day Registry Results Using a Second-Generation TF-TAVI System for the Treatment of Aortic Stenosis.
        in: Unknown Euro PCR 2016. Symetis SA, Paris2016
        • Barbanti M.
        • Petronio A.S.
        • Capodanno D.
        • Ettori F.
        • Colombo A.
        • Bedogni F.
        • et al.
        Impact of balloon post-dilation on clinical outcomes after transcatheter aortic valve replacement with the self-expanding CoreValve prosthesis.
        JACC Cardiovasc. Interv. 2014; 7: 1014-1021
        • Hahn R.T.
        • Pibarot P.
        • Webb J.
        • Rodes-Cabau J.
        • Herrmann H.C.
        • Williams M.
        • et al.
        Outcomes with post-dilation following transcatheter aortic valve replacement: the PARTNER I trial (placement of aortic transcatheter valve).
        JACC Cardiovasc. Interv. 2014; 7: 781-789